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Background: Physiologic wound repair and tissue regeneration are associated with distinct cellular behaviors
triggered by tissue damage. Normally quiescent stem cells proliferate to regenerate damaged tissue, while
relatively immobile epithelial cells can transform into a motile, tissue invasive phenotype through a partial
epithelial-mesenchymal transition. These distinct cellular behaviors may have particular relevance to how cancer
cells can be predicted to behave after treatments damaging a tumor.
Presentation of the hypothesis: Surgery, chemotherapy, and radiation therapy trigger highly conserved wound
healing pathways that: (1) facilitate the phenotypic transformation of surviving cancer cells into a highly mobile,
metastatic phenotype through an EMT or epithelial-mesenchymal transition and (2) induce residual cancer stem
cell proliferation.
Testing the hypothesis: Tissue damage caused by cancer treatments will trigger the release of distinct cytokines
with established roles in physiologic wound healing, EMT induction, and stem cell activation. They will be released
rapidly after treatment and detectable in the patient’s blood. Careful histologic evaluation of cancerous tissue
before and after treatment will reveal cellular changes suggestive of EMT induction (down regulation of cytokeratin
expression) and cancer stem cell enrichment (stem cell markers upregulated).
Implications of the hypothesis: Cancer cells surviving treatment will be more capable of metastasis and resistant
to conventional therapies than the pre-treatment population of cancer cells. These changes will develop rapidly
after treatment and, in distinct contrast to selection pressures fostering such changes, be triggered by highly
conserved wound repair signals released after tissue damage. This pattern of tissue (tumor) repair may be
amenable to treatment intervention at the time it is upregulated.
Background
Cancers of epithelial origin account for 90% of cancer
deaths worldwide. Their behavior has been compared to
an uncontrolled wound healing process for over a cen-
tury [1]. In more recent times Dvorak developed this
comparison further, describing the differences and simi-
larites between physiologic wound healing and the can-
cer induced formation of tumor stroma [2].
A distinct cellular behavior observed during wound
repair and tissue regeneration is epithelial mesenchymal
transition or EMT. An EMT is not a single phenotype,
but a general description of a cellular plasticity that can
vary from a transient increase in cellular mobility to a
complete molecular reprogramming [3]. It occurs in
response to different physiologic challenges, including
during embryonic development, tissue regeneration, and
cancer progression [4]. An EMT can be understood as a
biologic process enabling an epithelial cell to assume a
mesenchymal-like phenotype, providing that cell with
distinct capabilities. These include an enhanced ability
to migrate effectively; invade and degrade tissue through
matrix metalloproteinase (MMP) expression; an ability
to synthesize extracellular matrix components; and a
resistance to apoptosis during the anchorage indepen-
dent conditions associated with migration.
Fundamentally, EMT is a cellular alteration permitting
enhanced migration (Figure 1). Normally, epithelial cells
are held together tightly at junctions containing E-cad-
herin in complexes with catenins linked to the actin
cytoskeleton, limiting their migration. The dissolution of
these adhesive E-cadherin junctions is the hallmark of
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EMT. This can occur through the down regulation of
E-cadherin expression via negative transcriptional activa-
tors such as Snail and Twist [5,6], as well as through a
growth factor induced relocalization of E-cadherin [7,8].
A good example of an EMT like process occurring
during wound healing is re-epithelialization. After inci-
sional injury keratinocytes undergo transient phenotypic
changes similar to the more complete EMT changes
noted during developmental processes such as gastrula-
tion [9]. These changes include an enhanced migratory
ability through the disruption of cadherens junctions
and the ability to degrade tissue through metalloprotei-
nase expression. Another good example of an EMT like
process occurring during wound healing is the transfor-
mation of ovarian epithelial cells to a mesenchymal
phenotype under the influence of EGF during the post-
ovulatory repair of the damaged surface epithelium [10].
The molecular signals inducing EMT during wound
repair appear to emanate from damaged tissue microen-
vironments. Tissue injury triggers an acute inflammatory
response resulting in activation of the coagulation cas-
cade; platelet aggregation; and the proliferation of acti-
vated fibroblasts/inflammatory cells at the injury site
[11]. This induces the release of numerous soluble
inflammatory molecules and growth factors [12]. TGF
beta signaling, in cooperation with activation of various
receptor tyrosine kinases, is particularly important to the
induction of EMT in both physiologic and pathologic set-
tings [13]. The growth factors recognizing these receptors
with the strongest links to EMT induction include EGF
[10], FGF [14], HGF [15], PDGF [16], and IGF [17].
Closely aligned with wound healing is tissue regenera-
tion. Tissue specific stem cells are responsible for tissue
maintenance during the life of the organism, and they
can self-renew and produce daughter cells that can dif-
ferentiate into the more specialized cells comprising the
bulk of the tissue [18]. The molecular signals inducing
stem cell activation/proliferation are only now being dis-
covered, but similar to EMT induction, tissue damage
appears to be an important trigger. In the adult Droso-
phila intestine, which is an excellent model to study
stem cell behavior because intestinal stem cells are the
only mitotically active cell, tissue damage triggers a
rapid intestinal stem cell activation and proliferation
[19]. The mouse intestine is more complicated. The
three specialized cell types that comprise colonic epithe-
lium (enterocytes, goblet, and enteroendocrine cells) are
replenished by a population of colonic stem cells located
in distinct niches in the subepithelium known as the
crypts of Lieberkuhn. Tissue injury induces proliferation
and expansion of this cell population represented by an
elongation of these crypts [20]. Similarly, in the lungs of
mice suffering inhalational injury, the rapid generation
of large clonal cell patches representing active stem cell
proliferation is observed [21].
Presentation of the hypothesis
Surgery, chemotherapy, and radiation therapy, by dama-
ging both normal tissue as well as cancerous tissue, trig-
gers the release of highly conserved tissue repair
molecules that can facilitate both EMT induction and
stem cell activation in surviving cancer cells. These
molecules will be released rapidly after any treatment
that damages the tumor, paralleling the temporal pat-
tern of their rapid release during the acute inflammatory
phase of physiologic wound repair [11]. (Figure 2).
Testing the Hypothesis
That selection pressures imposed by cancer treatments
can lead to phenotypic changes in surviving cancer cells
is known. For example, a subclone of cancer cells resis-
tant to a given drug will be selected by that treatment
[22]. But what is not known is that damage to a tumor
through cancer treatments may also induce phenotypic
changes in surviving cancer cells purely as a highly
choreographed response to tissue injury, and that such
changes can facilitate the rapid emergence of a highly
aggressive, treatment resistant cancer cell phenotype.
To test this hypothesis acute inflammatory mediators
and cytokine levels important in physiologic wound
repair, EMT induction, and stem cell activation should
be evaluated immediately before and after initial treat-
ment against cancer. Post-treatment sampling should be
taken at 24, 48, 72, and 96 hours after treatment as well
as one, two weeks, and one month after treatment.
These time points encompass the time frame associated
with the acute and proliferative phases of a physiologic
wound repair response [11,12].
A distinct and replicable “wound healing pattern”
should be detectable in the serum or plasma of patients
after any cancer treatment, including surgery, che-
motherapy, or radiation. This pattern will reveal the
upregulated expression of growth factors with estab-
lished roles in EMT induction such as TGF-beta, HGF,
EGF, FGF, PDGF, and IGF as well as molecules now
known or eventually discovered to be important in stem
cell activation. Because cancer treatments will damage
Figure 1 Epithelial-Mesenchymal Transition. Normally epithelial
cells are held together tightly at cell-cell adherens junctions via
glycoprotein E-cadherin. An EMT leads to the breakdown of these
junctions and a motile (mesenchymal) and tissue invasive
phenotype.
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normal tissue as well as cancerous tissue, an important
corollary experiment is to sample molecular expression
profiles during the perioperative period in both benign
and neoplastic surgeries to see what may be unique
about cancer surgery. These surgeries should parallel
each other as much as possible in terms of the amount
of tissue damage to help limit the noise of a systemic
wound repair response to clarify what signals may be
unique about neoplastic surgery. For example, compare
the acute inflammatory expression profile in patients
who undergo wide local excision of a breast carcinoma
with patients who have surgical removal of benign
tumors such as fibroadenomas.
Histologic comparison of cancerous tissue before and
after treatment for evidence of EMT induction and stem
cell enrichment is another important experiment that
should be done. There is already evidence that cancer
treatments can result in residual cancer stem cell
enrichment, as conventional treatments can select for
treatment resistant cancer stem cells [22,23].
Distinguishing between residual cancer stem cell
enrichment triggered by a selection process or through
the release of tissue repair growth factors may be diffi-
cult, particularly after treatment with chemotherapy or
radiation therapy. To overcome this limitation one
could also compare tumor tissue before and after biopsy.
A core biopsy may damage tissue enough to induce a
wound repair response capable of inducing EMT and
stem cell activation. Careful comparison of core tissue
biopsy specimens with subsequent surgically removed
tumor tissue would be predicted to reveal the upregu-
lated expression of both stem cell markers as well as
markers of EMT. Such changes, if observed, could not
be considered as resulting from a selection process.
Implications of the Hypothesis
The remarkable phenotypic plasticity of epithelial cells is
integral to an adaptive repertoire necessary to form tis-
sue during development, as well as to regenerate and
repair damaged tissue during the life of the organism.
EMT induction confers a migratory and invasive epithe-
lial phenotype critical to tissue repair; stem cell activa-
tion provides the epithelial cell precursors necessary to
regenerate tissue. If this phenotypic plasticity and the
molecular triggers of that plasticity are preserved in
malignancies of epithelial origin, a profound shift needs
to occur in how we treat these tumors.
A rapid, even transient, phenotypic shift in cancer
cells to a more migratory, metastatic phenotype in
response to a treatment induced release of tissue repair
Figure 2 Hypothesis Schema. Treatments that damage a cancerous epithelial tumor are predicted to trigger a wound healing response that
will lead to EMT induction and cancer stem cell activation and proliferation as an adaptive response to tissue injury. This response, in turn, is
predicted to render surviving cancer cells resistant to conventional therapies and more capable of metastatic spread.
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signals has significant clinical implications. Cancer cell
populations that have undergone EMT or that are
enriched for cancer stem cells are highly resistant to
ionizing radiation, conventional chemotherapy, and
highly tumorigenic [24]. Disrupting the highly conserved
cytokine/signaling pathways important in EMT induc-
tion and stem cell activation at the time they are
released could prove highly effective as a treatment
strategy against residual cancer cells, preventing the
emergence of a treatment resistant, metastatic cancer
cell phenotype. Although this clinical strategy could be
employed after any treatment damaging the tumor, it
may be particularly effective in the potentially curative
adjuvant setting after the primary tumor has been surgi-
cally removed, limiting the ability of any surviving can-
cer cell population to proliferate and metastasize.
Merging the ancient concept that cancer behaves like
an aberrant wound healing process with our emerging
understanding of the importance of cancer stem cells in
tumor survival and regeneration provides a powerful
conceptual insight. This insight can be used to predict
how cancers of epithelial origin will behave in response
to cancer treatments. This knowledge, in turn, should
guide future treatment strategies and clinical trials.
These strategies should include not only what treat-
ments are likely to be effective but when those treat-
ments are likely to be effective, given that the
treatments themselves will induce a highly conserved
tissue repair response that can fundamentally alter the
phenotype of the cancer cells that survive treatment.
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